← All countries · Europe
96%
MCV1
2025 · WHO/UNICEF estimate
98%
DTP3
2025 · WHO/UNICEF estimate
98%
IPV complete
2025 · WHO/UNICEF estimate
97%
HepB3
2025 · WHO/UNICEF estimate
371
Measles cases
2025 reported
202
Pertussis (whooping cough) cases
2025 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | —% · Administrative (country-reported) | — | too few points | no data |
| DTP1First dose of diphtheria-tetanus-pertussis | 98%2025 · WHO/UNICEF estimate | — | B · good | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 98%2025 · WHO/UNICEF estimate | — | B · good | |
| IPV1First dose of inactivated polio vaccine | 99%2025 · WHO/UNICEF estimate | — | B · good | |
| IPV completeInactivated polio vaccine, complete primary series | 98%2025 · WHO/UNICEF estimate | — | D · poor | |
| MCV1First dose of measles-containing vaccine | 96%2025 · WHO/UNICEF estimate | — | B · good | |
| MCV2Second dose of measles-containing vaccine | 73%2025 · WHO/UNICEF estimate | — | B · good | |
| RCV1First dose of rubella-containing vaccine | 96%2025 · WHO/UNICEF estimate | — | B · good | |
| HepB3Third dose of hepatitis B vaccine | 97%2025 · WHO/UNICEF estimate | — | B · good | |
| HepB birthHepatitis B birth dose within 24 hours | —% · Administrative (country-reported) | — | too few points | no data |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 97%2025 · WHO/UNICEF estimate | — | B · good | |
| PCV1Pneumococcal conjugate vaccine, first dose | —% · Administrative (country-reported) | — | too few points | D · poor |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | 94%2025 · WHO/UNICEF estimate | — | B · good | |
| RotaCRotavirus vaccine, complete series | 86%2025 · WHO/UNICEF estimate | — | B · good | |
| Yellow feverYellow fever vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| MenAMeningococcal A conjugate (meningitis belt) | —% · Administrative (country-reported) | — | too few points | no data |
| JEJapanese encephalitis vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | —% · Administrative (country-reported) | — | too few points | no data |
| HPV dose 1, girlsHPV programme coverage, first dose, girls | 80%2025 · WHO/UNICEF estimate | — | B · good | |
| HPV complete, girlsHPV programme coverage, complete series, girls | 72%2025 · WHO/UNICEF estimate | — | B · good | |
| HPV dose 1, boysHPV programme coverage, first dose, boys | 73%2025 · WHO/UNICEF estimate | — | D · poor |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 3712025 | 31.6per 1,000,000 total population | B · good | |
| Rubella all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | A · strong | |
| Congenital rubella syndrome all countries · vaccine evidence | 02025 | 0per 10,000 live births | B · good | |
| Mumps all countries · vaccine evidence | 4032025 | 34.3per 1,000,000 total population | A · strong | |
| Pertussis (whooping cough) all countries · vaccine evidence | 2022025 | 17.2per 1,000,000 total population | A · strong | |
| Diphtheria all countries · vaccine evidence | 182025 | 1.5per 1,000,000 total population | A · strong | |
| Tetanus (total) all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Neonatal tetanus all countries · vaccine evidence | 02025 | 0per 1,000 live births | D · poor | |
| Polio (paralytic) all countries · vaccine evidence | 02021 | 0per 1,000,000 <15 population | D · poor | |
| Yellow fever all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Japanese encephalitis all countries · vaccine evidence | 02015 | 0per 1,000,000 total population | no data | |
| Invasive meningococcal disease all countries · vaccine evidence | 722025 | 6.1per 1,000,000 total population | C · weak | |
| Typhoid all countries · vaccine evidence | 372025 | 3.1per 1,000,000 total population | A · strong |
National schedule (latest WHO listing)
Show the schedule (65 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| COVID19COVID-19 vaccine | 1 | Adults | All older adults | |
| COVID19COVID-19 vaccine | 1 | Health workers | Health and care workers | |
| COVID19COVID-19 vaccine | 1 | Pregnant women | Pregnant women | |
| COVID19COVID-19 vaccine | 1 | Risk group(s) | Children and adolescents with chronic conditions, adults with chronic conditions, older adults with chronic conditions, other groups | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 1 | W8 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 2 | W12 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 3 | W16 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 4 | M15 | General/routine | |
| DTAPIPVDTaP-IPV (acellular) vaccine | 5 | Y5-Y6 | General/routine | |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | 1st contact | Catch-up children | First target group: recommended for newborns of HBsAg+ mothers, half an adult dose, at birth. Second target group: catch-up vaccination for children who weren't vaccinated with Hexa (schedule and dose varying according to age). Third target group: it is recommended for healthcare workers to be vaccinated against hep B in case they were not vaccinated with the combination vaccine as a child. For them, the vaccine is not reimbursed but costs will usually be covered by the employer. |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | 1st contact | Health workers | First target group: recommended for newborns of HBsAg+ mothers, half an adult dose, at birth. Second target group: catch-up vaccination for children who weren't vaccinated with Hexa (schedule and dose varying according to age). Third target group: it is recommended for healthcare workers to be vaccinated against hep B in case they were not vaccinated with the combination vaccine as a child. For them, the vaccine is not reimbursed but costs will usually be covered by the employer. |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | B | Risk group(s) | First target group: recommended for newborns of HBsAg+ mothers, half an adult dose, at birth. Second target group: catch-up vaccination for children who weren't vaccinated with Hexa (schedule and dose varying according to age). Third target group: it is recommended for healthcare workers to be vaccinated against hep B in case they were not vaccinated with the combination vaccine as a child. For them, the vaccine is not reimbursed but costs will usually be covered by the employer. |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 2 | +M1 | Catch-up children | First target group: recommended for newborns of HBsAg+ mothers, half an adult dose, at birth. Second target group: catch-up vaccination for children who weren't vaccinated with Hexa (schedule and dose varying according to age). Third target group: it is recommended for healthcare workers to be vaccinated against hep B in case they were not vaccinated with the combination vaccine as a child. For them, the vaccine is not reimbursed but costs will usually be covered by the employer. |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 2 | +M1 | Health workers | First target group: recommended for newborns of HBsAg+ mothers, half an adult dose, at birth. Second target group: catch-up vaccination for children who weren't vaccinated with Hexa (schedule and dose varying according to age). Third target group: it is recommended for healthcare workers to be vaccinated against hep B in case they were not vaccinated with the combination vaccine as a child. For them, the vaccine is not reimbursed but costs will usually be covered by the employer. |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 3 | +M6 | Catch-up children | First target group: recommended for newborns of HBsAg+ mothers, half an adult dose, at birth. Second target group: catch-up vaccination for children who weren't vaccinated with Hexa (schedule and dose varying according to age). Third target group: it is recommended for healthcare workers to be vaccinated against hep B in case they were not vaccinated with the combination vaccine as a child. For them, the vaccine is not reimbursed but costs will usually be covered by the employer. |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 3 | +M6 | Health workers | First target group: recommended for newborns of HBsAg+ mothers, half an adult dose, at birth. Second target group: catch-up vaccination for children who weren't vaccinated with Hexa (schedule and dose varying according to age). Third target group: it is recommended for healthcare workers to be vaccinated against hep B in case they were not vaccinated with the combination vaccine as a child. For them, the vaccine is not reimbursed but costs will usually be covered by the employer. |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 1 | Y12-Y14 | HPV administered to females and males | Y12 in Dutch- and German-speaking community. Y13-Y14 in French-speaking community |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 2 | +M6 | HPV administered to females and males | Y12 in Dutch- and German-speaking community. Y13-Y14 in French-speaking community |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | >=Y65 | Adults | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Health workers | Health and care workers | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Pregnant women | Pregnant women | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Risk group(s) | Adults with chronic conditions, residents living in long-term care facilities, other groups | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | Risk group(s) | Children with chronic conditions | |
| IPVIPV (Inactivated polio vaccine) | 1 | <M18 | Catch-up children | In case no hexavalent vaccine is given, 3 doses with 1 month interval. |
| IPVIPV (Inactivated polio vaccine) | 1 | 1st contact | Risk group(s) | Asylumseekers from country were polio is still endemicasap after arrival: if <5 months old via normal schedule, if >5 months old via catch-up vaccination schedule. |
| IPVIPV (Inactivated polio vaccine) | 2 | +M1 | Catch-up children | In case no hexavalent vaccine is given, 3 doses with 1 month interval. |
| IPVIPV (Inactivated polio vaccine) | 3 | +M1 | Catch-up children | In case no hexavalent vaccine is given, 3 doses with 1 month interval. |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 1 | M15 | General/routine | Children born <37w gestation receive dose 1 at 13 months. Booster dose at Y15 is recommended by the NITAG but it is not included in the free regional vaccination program (except in the German-speaking community). |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 1 | M13 | Risk group(s) | Children born <37w gestation receive dose 1 at 13 months. Booster dose at Y15 is recommended by the NITAG but it is not included in the free regional vaccination program (except in the German-speaking community). |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 2 | Y15-Y16 | General/routine | Children born <37w gestation receive dose 1 at 13 months. Booster dose at Y15 is recommended by the NITAG but it is not included in the free regional vaccination program (except in the German-speaking community). |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | M12 | General/routine | Y7-Y8 in French- and German-speaking community. Y9 in Dutch-speaking community. Since October 2025, MMR2 is given at 24 months in the Dutch-speaking community. In the other communities, it remains at age 7-8 |
| MMRMMR (Measles, mumps and rubella) vaccine | 2 | M24-Y9 | General/routine | Y7-Y8 in French- and German-speaking community. Y9 in Dutch-speaking community. Since October 2025, MMR2 is given at 24 months in the Dutch-speaking community. In the other communities, it remains at age 7-8 |
| MPOXMpox (monkeypox) vaccine | 1 | 1st contact | Risk group(s) | See NITAG advice (revised March 2026): https://www.hgr-css.be/file/download/357dafeb-6eb0-4546-adfb-f1ffd010b010/PYIX9mafWRRWpFUtHJ7nNWSopESmD2CqZLI0xr3wKo3d.pdf |
| MPOXMpox (monkeypox) vaccine | 2 | +M1 | Risk group(s) | See NITAG advice (revised March 2026): https://www.hgr-css.be/file/download/357dafeb-6eb0-4546-adfb-f1ffd010b010/PYIX9mafWRRWpFUtHJ7nNWSopESmD2CqZLI0xr3wKo3d.pdf |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 1 | W8 | General/routine | |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 2 | W16 | General/routine | |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 2 | W12 | Risk group(s) | Children born before 37 weeks of gestation get an extra dose at W12. |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 3 | M12 | General/routine | |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 1 | Y65 | Adults | All adults 65+; adults 18-64 with comorbidities or with increased of pneumococcal infections. |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 1 | W8 | General/routine | This vaccine is since 2025 recommended by the NITAG for childhood vaccination instead of PCV13. However, at the moment PCV13 is still the vaccine used in the free vaccination programs. |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 1 | Risk group(s) | All adults 65+; adults 18-64 with comorbidities or with increased of pneumococcal infections. | |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 2 | W16 | General/routine | This vaccine is since 2025 recommended by the NITAG for childhood vaccination instead of PCV13. However, at the moment PCV13 is still the vaccine used in the free vaccination programs. |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 3 | W24 | General/routine | This vaccine is since 2025 recommended by the NITAG for childhood vaccination instead of PCV13. However, at the moment PCV13 is still the vaccine used in the free vaccination programs. |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 4 | M12 | General/routine | This vaccine is since 2025 recommended by the NITAG for childhood vaccination instead of PCV13. However, at the moment PCV13 is still the vaccine used in the free vaccination programs. |
| PPV23PPV-23 (Pneumococcal polysaccharide 23-valent) vaccine | 1 | Y65 | Adults | This vaccine was recommended for older adults, as alternative for PCV20, and as a booster dose for persons with underlying medical conditions and increased risk of severe pneumococcal disease. In December 2025 the recommendation changed and this vaccine is no longer recommended. |
| PPV23PPV-23 (Pneumococcal polysaccharide 23-valent) vaccine | 1 | Risk group(s) | This vaccine was recommended for older adults, as alternative for PCV20, and as a booster dose for persons with underlying medical conditions and increased risk of severe pneumococcal disease. In December 2025 the recommendation changed and this vaccine is no longer recommended. | |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 1 | W8 | General/routine | Both RV-1 and RV-5 are used. Rotavirus vaccination is recommended for all in the basic schedule, but is not included in the free vaccination program. |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 2 | W12 | General/routine | Both RV-1 and RV-5 are used. Rotavirus vaccination is recommended for all in the basic schedule, but is not included in the free vaccination program. |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 1 | W8 | General/routine | Both RV-1 and RV-5 are used. Rotavirus vaccination is recommended for all in the basic schedule, but is not included in the free vaccination program. |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 2 | W12 | General/routine | Both RV-1 and RV-5 are used. Rotavirus vaccination is recommended for all in the basic schedule, but is not included in the free vaccination program. |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 3 | W16 | General/routine | Both RV-1 and RV-5 are used. Rotavirus vaccination is recommended for all in the basic schedule, but is not included in the free vaccination program. |
| RSVRSV (Respiratory syncytial virus) vaccine | 1 | Y75 | Adults | Aged 75 and older |
| RSVRSV (Respiratory syncytial virus) vaccine | 1 | Pregnant women | Maternal vaccine (Abrysvo) for women expected to deliver between early September and end of March | |
| RSVRSV (Respiratory syncytial virus) vaccine | 1 | Y60 | Risk group(s) | People aged 60 and above with: at least one risk factor for severe RSV, immunocompromised patients, or living in a nursing home |
| RSV_MONORSV (Respiratory syncytial virus) monoclonal antibodies | 1 | B | General/routine | births in the period October 1, 2024 – February 17, 2025; births in the period April 1 – September 30, 2024 |
| RSV_MONORSV (Respiratory syncytial virus) monoclonal antibodies | 1 | Y1-Y2 | Risk group(s) | For Children at increased risk of severe disease Nirsevimab is also recommended during their second RSV season (1-2 years old) |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 1 | Y25 | Adults | Adults Y25 and booster every 10 years after that. Pregnant women (each pregnancy) between 24 and 32 weeks of pregnancy, and their close environment (cocoon vaccination). Healthcare and child care staff who didn't get a booster in the last 10 years are also specifically recommended to get vaccinated |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 1 | Health workers | Adults Y25 and booster every 10 years after that. Pregnant women (each pregnancy) between 24 and 32 weeks of pregnancy, and their close environment (cocoon vaccination). Healthcare and child care staff who didn't get a booster in the last 10 years are also specifically recommended to get vaccinated | |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 1 | Pregnant women | Adults Y25 and booster every 10 years after that. Pregnant women (each pregnancy) between 24 and 32 weeks of pregnancy, and their close environment (cocoon vaccination). Healthcare and child care staff who didn't get a booster in the last 10 years are also specifically recommended to get vaccinated | |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 2 | +Y10 | Adults | Adults Y25 and booster every 10 years after that. Pregnant women (each pregnancy) between 24 and 32 weeks of pregnancy, and their close environment (cocoon vaccination). Healthcare and child care staff who didn't get a booster in the last 10 years are also specifically recommended to get vaccinated |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 3 | +Y10 | Adults | Adults Y25 and booster every 10 years after that. Pregnant women (each pregnancy) between 24 and 32 weeks of pregnancy, and their close environment (cocoon vaccination). Healthcare and child care staff who didn't get a booster in the last 10 years are also specifically recommended to get vaccinated |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 4 | +Y10 | Adults | Adults Y25 and booster every 10 years after that. Pregnant women (each pregnancy) between 24 and 32 weeks of pregnancy, and their close environment (cocoon vaccination). Healthcare and child care staff who didn't get a booster in the last 10 years are also specifically recommended to get vaccinated |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 5 | +Y10 | Adults | Adults Y25 and booster every 10 years after that. Pregnant women (each pregnancy) between 24 and 32 weeks of pregnancy, and their close environment (cocoon vaccination). Healthcare and child care staff who didn't get a booster in the last 10 years are also specifically recommended to get vaccinated |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 6 | +Y10 | Adults | Adults Y25 and booster every 10 years after that. Pregnant women (each pregnancy) between 24 and 32 weeks of pregnancy, and their close environment (cocoon vaccination). Healthcare and child care staff who didn't get a booster in the last 10 years are also specifically recommended to get vaccinated |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 6 | Y14-Y16 | General/routine |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.